Upstream Processing

Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.

Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.

The latest advances in upstream technologies include single-use equipment and a protein analyzer for titer monitoring, as well as new plasmid DNA manufacturing capability.

Accelerated approval pathways and growing demand for cell and gene therapies are putting pressure on providers of cellular starting materials, and they must ensure a steady supply.

Modeling is being used for everything from yield improvement to facility design, but new initiatives plan to broaden its reach, both upstream and downstream.

Used with perfusion, alternating tangential flow and tangential flow filtration are redefining upstream efficiency.

Leveraging automation and a step-by-step approach are keys to success.

In an effort to secure a continuous, sustainable supply of an important vaccine ingredient, Agenus is turning to a plant cell-based cell culture method for production.

The editors welcome technical article contributions from biopharma industry experts.

The evolution of cell-culture technology is driving the need for improvements in modeling solutions.

The partners will collaborate to identify the bioactive components in hydrolysates, which have long been used as additives in cell culture media and feed formulation in the biopharma industry.

Successful process intensification with inline dilution requires effective monitoring and control.

Using a QbD approach from early-stage development through commercialization can ensure that upstream processes are efficient and reliable.

Single-use systems offer a solution to the challenges inherent in buffer preparation, which can be the cause of bottlenecking in bioprocessing.

This article provides a review of various 2000-L single-use bioreactors used by biopharmaceutical suppliers for commercial production.

As cost and time pressures within biopharma are on the rise, innovative expression systems may offer companies a good opportunity to streamline processes early on.

BioPharm International speaks with several experts to learn more about pipeline platforms and technologies.

The Vaccine Development and Bioprocess Cell Culture Technology Day will take place on May 16, 2019 in Baltimore, MD.

Recent upstream processing innovations include enhanced sensor technology, single-use bioreactors, and automated cell culture systems.

The BioContinuum Buffer Delivery Platform offers streamlined buffer management and delivers “contiGuous” bioprocessing.

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

3D printing offers a new design freedom for bio/pharmaceutical manufacturing: whether for “printing” a solid-dosage drug or for creating a piece of equipment for bio/pharmaceutical laboratories or manufacturing facilities.

The company has launched a comprehensive portfolio of custom cell biology solutions and a new cell-line engineering technology.

Distek, a provider of laboratory testing instruments, added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.

Automation in cell-line development and cell culture is leading to more consistent quality while improving efficiency, and, ultimately, speed to market.

A new facility in California will expand Orchard Therapeutic’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells.

Advances in single-use technologies, sensors, and cell retention systems facilitate processes designed for the long run.

Recent equipment and updated product options offer improvement to a range of biopharmaceutical manufacturing tasks.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.

This article will explore the requirements for media and supplements needed to maintain newer cell lines, such as those based on human cells and fungal cells.